EWAF
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
01/04/2025
Back to search
Official data from USPTO
ENTOS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
ENTOS
ST13
US500000097977591Class
40, 42, 44
Filing
97977591
Registration
7446491
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
32
Latest update
01/08/2025
Classification
Registered
Trademark type
Word
Nice classes
40, 42, 44
Filing date
09/14/2022
Registration date
07/16/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/16/2024
Last transaction
01/08/2025
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Foreign priority
First use anywhere
2011-04-00
First use in commerce
01/23/2018
Drawing code
4
Owner type
03
Owner location
EDMONTON, AB, CA
Examiner
HENRY,NAKIA D
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
Entos Pharmaceuticals Inc.
Entos Pharmaceuticals Inc.
Representatives
Theodore R. Remaklus Thompson Hine LLP
Technical classification
Nice Classes
Class 40Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 40
Custom manufacture of pharmaceuticalspharmaceutical ingredientshuman vaccinestherapeutic proteins and antibodies for others; custom manufacturing of pharmaceuticalspharmaceutical ingredientshuman vaccinestherapeutic proteins and antibodies
Class 42
Advisory services relating to gene therapy research; research in the field of gene therapy; research and development of vaccines and medicines; information on the subject of scientific research in the field of biotechnology; genetic testing for scientific research purposes; scientific research in the field of genetics and genetic engineering; research and development in the pharmaceutical and biotechnology fields; pharmaceutical research and development in the field of therapeutic and diagnostic products; scientific researchpharmaceutical researchmedical researchtechnical consultation in the field of pharmaceutical studies and product development for others in the field of biotechnology and product development of pharmaceuticalstherapeutic agents and medical devices; research and product development in the field of human vaccinesrecombinant proteins and antibodies for therapeutic use; high-throughput vaccine engineering services; medical and scientific research services of proprietary recombinant protein platform technologies designed to lead to new human vaccinestherapeutic proteins and antibodies; medical and scientific research services relating to infectious diseases; development of new products for others in the field of pharmaceuticalspharmaceutical ingredientshuman vaccinestherapeutic proteins and antibodies; medical and scientific research regarding clinical trial studies on new vaccine candidates
Class 44
Medical therapy servicesgene therapy services; medical analysis servicesRNA or DNA analysis for virus diagnosis and prognosis; medical information servicesproviding information to physicianshealthcare professionals and patients on the topics of health issues that can be treated with vaccinesrecombinant proteins and antibodiesdiagnosticprophylactic and therapeutic properties of vaccinesrecombinant proteins and antibodies; on-line information servicesproviding medical information to physicianshealthcare professionals and patients on the topics of health issues that can be treated with vaccinesrecombinant proteins and antibodiesdiagnosticprophylactic and therapeutic properties of vaccinesrecombinant proteins and antibodies; genetic testing for medical purposes
Publications
History of USPTO decisions and trademark events.
32 publications found
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/04/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/04/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/04/2025
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
01/04/2025
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
01/04/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/16/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
07/16/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/30/2024
PUBO
PUBLISHED FOR OPPOSITION
04/30/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/10/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/22/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
03/12/2024
ALIE
ASSIGNED TO LIE
03/11/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
03/11/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
03/11/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/11/2024
DPCC
DIVISIONAL PROCESSING COMPLETE
03/08/2024
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/06/2024
DRRR
DIVISIONAL REQUEST RECEIVED
11/16/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/16/2023
AMPX
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
11/16/2023
PARI
TEAS VOLUNTARY AMENDMENT RECEIVED
11/16/2023
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
11/16/2023
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
09/27/2023
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
09/27/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/27/2023
GNRT
NON-FINAL ACTION E-MAILED
06/27/2023
CNRT
NON-FINAL ACTION WRITTEN
06/27/2023
DOCK
ASSIGNED TO EXAMINER
06/26/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/29/2022
NWAP
NEW APPLICATION ENTERED
09/17/2022
Continuous trademark protection
Get notified about every new filing that threatens ENTOS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.